Form 4: OptiNose Director Dempsey Reports Stock Option Changes Following Merger with Paratek Pharmaceuticals

Director Kyle Dempsey reports changes in stock option holdings due to the merger between OptiNose and Paratek Pharmaceuticals, including cash consideration and contingent value rights.

Summary

• On May 21, 2025, OptiNose, Inc. merged with Orca Merger Sub, a subsidiary of Paratek Pharmaceuticals, with OptiNose continuing as the surviving entity.
• As a result of the merger, each outstanding share of OptiNose common stock was converted into the right to receive $9.00 in cash and one contingent value right (CVR).
• The CVR represents the right to receive up to $5.00 in cash in two contingent payments upon achievement of specified milestones.
• Outstanding stock options were converted into the right to receive cash equal to the excess of $9.00 over the exercise price, with certain options canceled depending on their exercise price.
• Stock options with an exercise price greater than $14.00 were canceled for no consideration.
• Stock options with an exercise price greater than $9.00 but less than $14.00 were canceled and converted into the right to receive one CVR, reduced by the amount the exercise price exceeds $9.00.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily detailing the mechanics of the merger and its impact on stock options. The sentiment is moderately positive due to the cash consideration and potential for additional value through CVRs, but tempered by the cancellation of some stock options.

Positives

• Shareholders received $9.00 in cash per share as part of the merger agreement.
• The contingent value right (CVR) provides an opportunity for additional payments of up to $5.00 per share based on milestone achievements.

Negatives

• Stock options with an exercise price exceeding $14.00 were canceled without any compensation.
• The value of the CVR is contingent on the achievement of specific milestones, which may not be realized.

Risks

• The contingent payments associated with the CVR are not guaranteed and depend on the successful achievement of specified milestones.
• The actual value received from the CVR may be less than the maximum potential payment of $5.00.

Future Outlook

The future value of the CVRs depends on the achievement of milestones as specified in the CVR Agreement.

Industry Context

This merger reflects a trend of consolidation in the pharmaceutical industry, where companies seek to expand their product portfolios and market reach through acquisitions.

Comparison to Industry Standards

• Mergers in the pharmaceutical industry often involve a combination of upfront cash payments and contingent value rights (CVRs) to bridge valuation gaps and align the interests of both parties.
• The structure of this deal, with a $9.00 cash payment and a CVR, is similar to other acquisitions in the biotech space, such as Sanofi's acquisition of Translate Bio, which also included CVRs tied to specific milestones.
• The success of the CVR component will depend on OptiNose's ability to achieve the specified milestones, which is a common risk factor in these types of deals.

Stakeholder Impact

• Shareholders received cash and CVRs, impacting their investment value.
• Employees may experience changes due to the integration of OptiNose into Paratek Pharmaceuticals.
• Option holders with exercise prices above certain thresholds will have their options cancelled.

Key Dates

Keywords

Merger, OptiNose, Paratek Pharmaceuticals, Stock Options, Contingent Value Right, CVR, Cash Consideration